1 / 6

Bivalirudin Drug as Alternative to Heparin for Anticoagulation in Children and I

Bivalirudin is a synthetic residue peptide and it is direct thrombin inhibitor (DTI). It is an anticoagulant that helps to prevent the formation of blood clots, especially in people with severe chest pain or ones who are undergoing angioplasty.

Pooja63
Download Presentation

Bivalirudin Drug as Alternative to Heparin for Anticoagulation in Children and I

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BIVALIRUDIN DRUG MARKET Global Industry Analysis, Size, Share, Analysis, Growth, Forecast 2018 - 2028 Trends, and TMR Research www.tmrresearch.com

  2. BIVALIRUDIN DRUG MARKET 1MARKETOVERVIEW Bivalirudin is a synthetic residue peptide and it is direct thrombin inhibitor (DTI). It is an anticoagulant that helps to prevent the formation of blood clots, especially in people with severe chest pain or ones who are undergoing angioplasty. Bivalirudin is for IV use only and it is supplied as a sterile, lyophilized product, and glass vials. TMR Research www.tmrresearch.com

  3. BIVALIRUDIN DRUG MARKET 2KEY TRENDS Bivalirudin has emerged as an alternative for heparin for infants and children in anticoagulation. Moreover, Bivalirudin, unlike heparin, does not require antithrombin to be effective, thus providing more consistent anticoagulation. TMR Research www.tmrresearch.com

  4. BIVALIRUDIN DRUG MARKET 3MARKETPOTENTIAL The acute coronary syndrome is emerging as the most common cause of death globally. This is driving the demand for Percutaneous Coronary Intervention (PCI) to manage acute coronary syndrome. In order to reduce the risk of thrombotic complications, the use of anticoagulation therapy is increasing during PCI, thereby, driving the demand for Bivalirudin drug as the anticoagulant drug as it reduces the risk of bleedingduringtheprocedure. TMR Research www.tmrresearch.com

  5. BIVALIRUDIN DRUG MARKET 4COMPETITVE ANALYSIS Aurobindo operations Netherlands, Republic.Beximo Pharmaceuticals Limited plans to buy eight ANDAs in the US from Sandoz Inc., a division of Novartis. Following this deal, Beximo Pharma will have 14 approved ANDAs in its product portfolio in the US. Pharma in Belgium, has European Poland, acquired commercial including and the Apotex’s countries Spain, five the Czech TMR Research www.tmrresearch.com

  6. TMR Research www.tmrresearch.com Sample Discount Check link in description

More Related